Scholarlink

In many ovarian cancer clinical trials, the HRD score cutoff was established based on a combined analysis of breast and ovarian cancers, using The Cancer Genome Atlas (TCGA) data and two custom SNP array panels. We examined the optimal HRD score cutoff value in HGSOC using 296 cases with SNP array and exome sequencing data from HGSOC published in TCGA. To determine the optimal timing for HRD testing, we analyzed changes in HRD status before and after chemotherapy, as well as at initial treatment and recurrence. We analyzed intra-tumoral heterogeneity, HRD scores, and copy number variations. Analysis of these matched samples revealed a significant decrease in HRD score at IDS compared with that at initial treatment. Furthermore, there was no significant change in HRD score of matching samples between initial treatment and recurrence. Our analysis revealed that the HRD test results may be influenced by chemotherapy, necessitating careful consideration of the timing of specimen. collection for HRD testing. Based on these results, we proposed a hypothesis regarding the clinical course of HRD tumors, and we considered the optimal treatment strategy gynecologic oncologists should pursue in the era of PARP inhibitors.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Timing and Cutoff Line of My Choice HRD Test

  • 章节

  • 发表日期：

    2026年

查看全文
  • Hidekatsu Nakai,
  • Hisamitsu Takaya,
  • Noriomi Matsumura

摘要

In many ovarian cancer clinical trials, the HRD score cutoff was established based on a combined analysis of breast and ovarian cancers, using The Cancer Genome Atlas (TCGA) data and two custom SNP array panels. We examined the optimal HRD score cutoff value in HGSOC using 296 cases with SNP array and exome sequencing data from HGSOC published in TCGA. To determine the optimal timing for HRD testing, we analyzed changes in HRD status before and after chemotherapy, as well as at initial treatment and recurrence. We analyzed intra-tumoral heterogeneity, HRD scores, and copy number variations. Analysis of these matched samples revealed a significant decrease in HRD score at IDS compared with that at initial treatment. Furthermore, there was no significant change in HRD score of matching samples between initial treatment and recurrence. Our analysis revealed that the HRD test results may be influenced by chemotherapy, necessitating careful consideration of the timing of specimen. collection for HRD testing. Based on these results, we proposed a hypothesis regarding the clinical course of HRD tumors, and we considered the optimal treatment strategy gynecologic oncologists should pursue in the era of PARP inhibitors.